2011
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161: 298-306.e1. PMID: 21315212, DOI: 10.1016/j.ahj.2010.10.035.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsGP IIb/IIIa inhibitorsAcute coronary syndromeBivalirudin monotherapyMajor bleedingCoronary syndromePlatelet countClinical consequencesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsPredictors of mortalityAcquired thrombocytopeniaACUITY trialAcute CatheterizationAntiplatelet medicationsAntithrombotic therapyIschemic complicationsAnticoagulant regimenIndependent predictorsStrategy trialThrombocytopeniaPatientsMultivariate analysisMonotherapyLess decline
2009
Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMI
2008
Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. Journal Of The American College Of Cardiology 2008, 52: 807-814. PMID: 18755342, DOI: 10.1016/j.jacc.2008.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationEnoxaparinFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk FactorsTime FactorsConceptsIIb/IIIa inhibitorsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsHigh-risk ACS patientsImpact of bivalirudinUnfractionated heparinACUITY trialComposite ischemiaACS patientsCoronary interventionAcute coronary syndrome patientsEfficacy of bivalirudinLess major bleedingSimilar ischemic outcomesAcute coronary syndromeCoronary syndrome patientsBivalirudin monotherapyIschemic outcomesMajor bleedingCoronary syndromeSyndrome patientsBivalirudinPatientsEnoxaparinThe Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 2008, 156: 44-56. PMID: 18585496, DOI: 10.1016/j.ahj.2008.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHeparin, Low-Molecular-WeightHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProspective StudiesRecombinant ProteinsReference ValuesResearch DesignRisk AssessmentStentsSurvival RateThrombosisTime FactorsConceptsPrimary PCIPrimary percutaneous coronary interventionIIb/IIIa inhibitorsAcute myocardial infarctionBare metal stentsGP IIb/IIIa inhibitorsHORIZONS-AMI trialUnfractionated heparinGlycoprotein IIb/IIIa inhibitorsIdentical bare-metal stentOverall event-free survivalAcute Myocardial Infarction trialEnd pointDirect thrombin inhibitor bivalirudinRoutine useEfficacy end pointMyocardial Infarction trialTarget lesion revascularizationEvent-free survivalClinical end pointsPercutaneous coronary interventionPaclitaxel-eluting stentsNew pharmacologic agentsThrombin inhibitor bivalirudinDrug-eluting stents
2004
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 44: 305-312. PMID: 15261923, DOI: 10.1016/j.jacc.2004.03.058.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIIb/IIIa inhibitorsTissue-level perfusionMyocardial perfusionPrimary angioplastyMyocardial infarctionGlycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsClinical implicationsIIb/IIIa inhibitionSimilar long-term mortalityLarge-scale prospective studiesMechanical reperfusion strategiesLong-term mortalityMyocardial blush gradeMinority of patientsNormal myocardial perfusionDistinct risk categoriesBlush gradePrimary PCIReperfusion strategyMyocardial reperfusionBalloon angioplastyPrognostic importance
1998
Heparin dosing in patients undergoing coronary intervention
Popma J, Prpic R, Lansky A, Piana R. Heparin dosing in patients undergoing coronary intervention. The American Journal Of Cardiology 1998, 82: 19p-24p. PMID: 9809888, DOI: 10.1016/s0002-9149(98)00759-0.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsCoronary interventionHeparin therapyHemochron devicePlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsUncomplicated coronary interventionsWeight-adjusted heparinAntithrombotic regimenHemoTec deviceHeparin bolusHeparin dosingSufficient heparinHeparin administrationConventional heparinUnfractionated heparinSignificant thrombocytopeniaPatientsACT levelsHeparinLonger durationTarget ACTInterventionAnticoagulation